Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jubilant Ingrevia Limited (JUBLINGREA.NS)
Noida, IN
Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment delivers a variety of specialized ingredients, fine chemicals, and crop protection agents, in addition to offering custom development and manufacturing (CDMO) services. Its Nutrition & Health Solutions division focuses on ingredients for both human and animal nutrition and well-being. Meanwhile, the Life Science Chemicals segment provides crucial life science components and a range of specialized ethanol products. Jubilant Ingrevia's extensive portfolio encompasses numerous chemical offerings, including a broad spectrum of pyridine derivatives (such as picolines, cyanopyridines, and various substituted pyridines), essential vitamins like B3 and riboflavin phosphate sodium, and nutritional compounds like premixes and antioxidants. They also produce industrial chemicals like acetic anhydride, ethyl acetate, and various alcohols (absolute alcohol, ethanol), alongside biocompost and gas mixtures. Furthermore, the company supplies a wide array of animal health and nutrition additives, including mineral premixes, stress regulators, amino acids, herbal growth promoters, toxin binders, and enzymes. Beyond its product range, Jubilant Ingrevia offers specialized services in chemical synthesis, covering everything from initial route design and process optimization to scaling up production and commercial manufacturing of intermediates. The company serves a diverse client base across the pharmaceutical, nutrition, agrochemical, consumer goods, and industrial sectors. Originally incorporated as Jubilant LSI Limited, the company adopted its current name, Jubilant Ingrevia Limited, in October 2020.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.07% | -9.70% | -5.23% | +16.60% | -3.59% | -2.96% | -3.16% | +70.84% | +41.06% | +154.04% | +154.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 5 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | +1 |
-
Revenue growth Chemicals - Specialty: +4.7%+6.4% ★ Q1'26: +13.5% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+10.5% Q1'26: +16.2% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+6.0% Q1'26: -3.1% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+8.9% ★ Q1'26: +9.7% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+7.9% ★ Q1'26: +9.5% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+0.1% Q1'26: +0.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×1.40× Q1'26: 1.22× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 7 Rev. Ana. 6 EPS Ana. |
Mar 2027 6 Rev. Ana. 6 EPS Ana. |
Mar 2028 7 Rev. Ana. 7 EPS Ana. |
Mar 2029 2 Rev. Ana. 2 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
49.14B
est: 48.64B (+1.0%)
|
47.40B
est: 47.57B (-0.3%)
|
41.00B
est: 40.85B (+0.4%)
|
41.24B
est: 42.77B (-3.6%)
|
44.15B
43.03B – 44.94B
+3.2% YoY
|
52.32B
49.72B – 54.86B
+18.5% YoY
|
59.32B
50.12B – 64.32B
+13.4% YoY
|
69.18B
61.90B – 73.85B
+16.6% YoY
|
77.98B
69.77B – 83.24B
+12.7% YoY
|
| EBITDA |
8.59B
est: 6.77B (+26.9%)
|
5.79B
est: 6.62B (-12.5%)
|
4.56B
est: 5.49B (-17.0%)
|
5.56B
est: 5.75B (-3.3%)
|
5.94B
5.79B – 6.04B
+3.2% YoY
|
7.03B
6.69B – 7.38B
+18.5% YoY
|
7.98B
6.74B – 8.65B
+13.4% YoY
|
9.30B
8.32B – 9.93B
+16.6% YoY
|
10.49B
9.38B – 11.19B
+12.7% YoY
|
| EBIT |
7.36B
est: 5.28B (+39.5%)
|
4.57B
est: 5.16B (-11.4%)
|
3.20B
est: 4.17B (-23.3%)
|
3.98B
est: 4.36B (-8.7%)
|
4.50B
4.39B – 4.58B
+3.2% YoY
|
5.34B
5.07B – 5.60B
+18.5% YoY
|
6.05B
5.11B – 6.56B
+13.4% YoY
|
7.06B
6.31B – 7.53B
+16.6% YoY
|
7.95B
7.12B – 8.49B
+12.7% YoY
|
| Net Income |
4.77B
est: 5.68B (-16.0%)
|
3.07B
est: 3.06B (+0.5%)
|
1.83B
est: 1.74B (+5.1%)
|
2.51B
est: 2.47B (+1.7%)
|
2.71B
2.64B – 2.77B
+9.6% YoY
|
3.86B
3.82B – 4.64B
+42.7% YoY
|
4.78B
3.90B – 5.93B
+23.7% YoY
|
6.25B
6.21B – 6.32B
+30.9% YoY
|
7.05B
6.08B – 7.67B
+12.7% YoY
|
| SGA |
3.30B
est: 1.95B (+69.3%)
|
3.52B
est: 1.90B (+84.6%)
|
3.92B
est: 4.05B (-3.1%)
|
4.25B
est: 4.24B (+0.3%)
|
4.38B
4.27B – 4.46B
+3.2% YoY
|
5.19B
4.93B – 5.44B
+18.5% YoY
|
5.88B
4.97B – 6.38B
+13.4% YoY
|
6.86B
6.14B – 7.32B
+16.6% YoY
|
7.73B
6.92B – 8.25B
+12.7% YoY
|
| EPS |
29.98
est: 35.80 (-16.3%)
|
19.34
est: 19.30 (+0.2%)
|
11.56
est: 11.01 (+5.0%)
|
15.89
est: 15.95 (-0.4%)
|
17.16
16.65 – 17.44
+7.6% YoY
|
25.66
24.06 – 29.21
+49.5% YoY
|
32.19
24.57 – 37.39
+25.4% YoY
|
39.45
39.10 – 39.80
+22.6% YoY
|
44.40
38.33 – 48.30
+12.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.01% | 2.00M | 0.06% |
| 2 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 63.4K | 0.48% |
| 3 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 142.9K | 0.26% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 7.05M | 0.06% |
| 5 | Vanguard ESG International Stock ETF VSGX | 0.00% | 138.6K | 0.10% |
| 6 | Vanguard Total International Stock ETF VXUS | 0.00% | 7.75M | 0.05% |
| 7 | Vanguard Total World Stock ETF VT | 0.00% | 549.2K | 0.06% |
| 8 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 11.3K | 0.22% |
| 9 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 34.1K | 0.22% |
| 10 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 18.4K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hari Shanker Bhartia | Co-Chairman & Whole-Time Director | 184M | male |
| Deepak Jain | Chief Executive Officer, MD & Director | 128M | male |
| Vijay Kumar Srivastava | Chief of Operations & Whole Time Director | 9M | male |
| Deepanjali Gulati | Company Secretary & Compliance Officer | 5M | female |
| Sanjeev Kumar | Vice President and Head of Quality & Regulatory Affairs | — | male |
| Varun Gupta | President & Chief Financial Officer | — | male |
| Ambrish Dixit | President of Speciality Chemicals | — | male |
| Vinita Koul | Senior Vice President & Head of Human Resources | — | female |
| Ashish Kumar Sinha | Business Head of Animal & Human Nutrition | — | male |
| Himanshu Dhapolav | Business Head of Acetyls | — | male |
| Sanjay Gupta | Executive Vice President & Head of Legal | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JUBLINGREA.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
